The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
Latest news from ARC
Breaking News: First treatment for AL Amyloidosis approved in US
Daratumumab has just been granted approval by the FDA for the treatment of AL Amyloidosis in the United States. Today marks a major milestone and an achievement that has been years in the making. Janssen applied for FDA approval for subcutaneous daratumumab (Darzalex Faspro) this summer for the treatment of AL Amyloidosis. It was previously approved for the treatment of multiple myeloma, and trials showed remarkable promise for its use in AL amyloidosis. The application is based on data from...
Managing GI Issues in Amyloidosis – FAQ
Dr. John Clarke from Stanford University presented in a recent ARC Talks webinar on Gastro Intestinal Disturbances and Symptom Relief for Amyloidosis. This report covers the most frequently asked questions and recommendations.
My Amyloidosis Pathfinder
MAP is a free, easy-to-use tool that captures your treatment preferences, goals, and challenges so you can effectively communicate with your amyloidosis care teams. You can also find and compare specialty treatment centers and receive personalized matches to clinical trials.Get Started